Earnings Per Share, Diluted in USD/shares of Ambrx Biopharma Cayman, Inc. from 2021 to Q2 2023

Taxonomy & unit
us-gaap: USD/shares
Description
The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
Summary
Ambrx Biopharma Cayman, Inc. quarterly and annual Earnings Per Share, Diluted history and change rate from 2021 to Q2 2023.
  • Ambrx Biopharma Cayman, Inc. Earnings Per Share, Diluted for the quarter ending 30 Jun 2023 was -0.05, a 55% increase year-over-year.
  • Ambrx Biopharma Cayman, Inc. annual Earnings Per Share, Diluted for 2022 was -0.29, a 40% increase from 2021.
Source SEC data
View on sec.gov
Earnings Per Share, Diluted, Quarterly (USD/shares)
Earnings Per Share, Diluted, YoY Quarterly Change (%)
Earnings Per Share, Diluted, Annual (USD/shares)
Earnings Per Share, Diluted, YoY Annual Change (%)

Ambrx Biopharma Cayman, Inc. Quarterly Earnings Per Share, Diluted (USD/shares)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q2 2023 -0.05 +0.06 +55% 01 Apr 2023 30 Jun 2023 10-Q 09 Aug 2023 2023 Q2
Q1 2023 -0.05 +0.03 +38% 01 Jan 2023 31 Mar 2023 10-Q 11 May 2023 2023 Q1
Q2 2022 -0.11 01 Apr 2022 30 Jun 2022 10-Q 09 Aug 2023 2023 Q2
Q1 2022 -0.08 01 Jan 2022 31 Mar 2022 10-Q 11 May 2023 2023 Q1

Ambrx Biopharma Cayman, Inc. Annual Earnings Per Share, Diluted (USD/shares)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2022 -0.29 +0.19 +40% 01 Jan 2022 31 Dec 2022 10-K 30 Mar 2023 2022 FY
2021 -0.48 01 Jan 2021 31 Dec 2021 10-K 30 Mar 2023 2022 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.